Pancreatic cancer and personalized medicine: Can genomics facilitate early diagnosis or improve therapeutic outcomes?

Current Pharmacogenomics and Personalized Medicine

Volumn 8, Issue 1, 2010, Pages 73-88

  Strimpakos, A S ^a   Hoimes, C ^b   Syrigos, K N ^a,b   Saif, M W ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b YALE CANCER CENTER   (United States)

Author keywords

Early diagnosis; Genomics; Pancreatic cancer; Postgenomics medicine; Targeted oncopharmacology

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; BEVACIZUMAB; CA 19-9 ANTIGEN; CAPECITABINE; CETUXIMAB; CISPLATIN; CURCUMIN; CYCLINE; CYCLOOXYGENASE 2; DEOXYCYTIDINE KINASE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IMC C2225; IRINOTECAN; MATRIX METALLOPROTEINASE; MATUZUMAB; MEMBRANE PROTEIN; OXALIPLATIN; PACLITAXEL; PROTEIN P53; SMAD4 PROTEIN; SORAFENIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; CANCER DIAGNOSIS; CANCER RESISTANCE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; ENDOSCOPY; GENE MUTATION; GENETIC POLYMORPHISM; GENOMICS; HUMAN; LABORATORY TEST; ONCOGENE; ONCOGENE K RAS; ONCOGENE NEU; PANCREAS CANCER; PHARMACOGENOMICS; PROGNOSIS; PROTEIN EXPRESSION; RADIODIAGNOSIS; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

EID: 77950284740     PISSN: 18756921     EISSN: 18756913     Source Type: Journal    
DOI: 10.2174/1875692111008010073     Document Type: Review

References (148)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58(2): 71-96.
2. Dalton RR, Sarr MG, van Heerden JA, et al. Carcinoma of the body and tail of the pancreas: is curative resection justified? Surgery 1992; 111(5): 489-494
3. Strimpakos A, Saif MW, Syrigos KN. Pancreatic cancer: from molecular pathogenesis to targeted therapy. Cancer Metastasis Rev 2008; 27(3): 495-522.
4. Jalanko H, Kuusela P, Roberts P, et al. Comparison of a new tumour marker, CA 19-9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases. J Clin Pathol 1984; 37(2): 218-222
5. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 1990; 85(4): 350-355
6. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24(33): 5313-5327
7. Saif MW. Translational research in pancreatic cancer. JOP 2008; 9(4): 398-402.
8. Nagata K, Horinouchi M, Saitou M, et al. Mucin expression profile in pancreatic cancer and the precursor lesions. J Hepatobiliary Pancreat Surg 2007; 14(3): 243-254
9. Yonezawa S, Nakamura A, Horinouchi M, et al. The expression of several types of mucin is related to the biological behavior of pancreatic neoplasms. J Hepatobiliary Pancreat Surg 2002; 9(3): 328-341
10. Ueda M, Miura Y, Kunihiro O, et al. MUC1 overexpression is the most reliable marker of invasive carcinoma in intraductal papillarymucinous tumor (IPMT). Hepatogastroenterology 2005; 52(62): 398-403.
11. Almoguera C, Shibata D, Forrester K, et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988; 53(4): 549-554
12. Smit VT, Boot AJ, Smits AM, et al. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res 1988; 16(16): 7773-7782
13. Hruban RH, van Mansfeld AD, Offerhaus GJ, et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 1993; 143(2): 545-554
14. Kawesha A, Ghaneh P, Andren-Sandberg A, et al. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma. Int J Cancer 2000; 89(6): 469-474
15. Talar-Wojnarowska R, Gasiorowska A, Smolarz B, et al. Clinical significance of K-ras and c-erbB-2 mutations in pancreatic adenocarcinoma and chronic pancreatitis. Int J Gastrointest Cancer 2005; 35(1): 33-41.
16. Rozenblum E, Schutte M, Goggins M, et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997; 57(9): 1731-1734
17. Dergham ST, Dugan MC, Kucway R, et al. Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma. Int J Pancreatol 1997; 21(2): 127-143
18. Dong M, Nio Y, Yamasawa K, et al. p53 alteration is not an independent prognostic indicator, but affects the efficacy of adjuvant chemotherapy in human pancreatic cancer. J Surg Oncol 2003; 82(2): 111-120
19. Lowe SW. Cancer therapy and p53. Curr Opin Oncol 1995; 7(6): 547-553
20. Zhan M, Yu D, Lang A, et al. Wild type p53 sensitizes soft tissue sarcoma cells to doxorubicin by down-regulating multidrug resistance-1 expression. Cancer 2001; 92(6): 1556-1566
21. Lang D, Miknyoczki SJ, Huang L, et al. Stable reintroduction of wild-type P53 (MTmp53ts) causes the induction of apoptosis and neuroendocrine-like differentiation in human ductal pancreatic carcinoma cells. Oncogene 1998; 16(12): 1593-1602
22. Dong M, Ma G, Tu W, et al. Clinicopathological significance of p53 and mdm2 protein expression in human pancreatic cancer. World J Gastroenterol 2005; 11(14): 2162-2165
23. Nakamori S, Yashima K, Murakami Y, et al. Association of p53 gene mutations with short survival in pancreatic adenocarcinoma. Jpn J Cancer Res 1995; 86(2): 174-181
24. Gerdes B, Ramaswamy A, Ziegler A, et al. p16INK4a is a prognostic marker in resected ductal pancreatic cancer: an analysis of p16INK4a, p53, MDM2, an Rb. Ann Surg 2002; 235(1): 51-59
25. Wilentz RE, Iacobuzio-Donahue CA, Argani P, et al. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 2000; 60(7): 2002-2006
26. Schutte M, Hruban RH, Hedrick L, et al. DPC4 gene in various tumor types. Cancer Res 1996; 56(11): 2527-2530
27. Hua Z, Zhang YC, Hu XM, et al. Loss of DPC4 expression and its correlation with clinicopathological parameters in pancreatic carcinoma. World J Gastroenterol 2003; 9(12): 2764-2767
28. Tascilar M, Skinner HG, Rosty C, et al. The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res 2001; 7(12): 4115-4121
29. Khorana AA, Hu YC, Ryan CK, et al. Vascular endothelial growth factor and DPC4 predict adjuvant therapy outcomes in resected pancreatic cancer. J Gastrointest Surg 2005; 9(7): 903-911
30. Iacobuzio-Donahue CA, Fu B, Yachida S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 2009; 27(11): 1806-1813
31. Tsiambas E, Karameris A, Dervenis C, et al. HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis. JOP 2006; 7(3): 283-294
32. Stoecklein NH, Luebke AM, Erbersdobler A, et al. Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma. J Clin Oncol 2004; 22(23): 4737-4745
33. Dugan MC, Dergham ST, Kucway R, et al. HER-2/neu expression in pancreatic adenocarcinoma: relation to tumor differentiation and survival. Pancreas 1997; 14(3): 229-236
34. Tobita K, Kijima H, Dowaki S, et al. Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis. Int J Mol Med 2003; 11(3): 305-309
35. Bloomston M, Bhardwaj A, Ellison EC, et al. Epidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray technique. Dig Surg 2006; 23(1-2): 74-79
36. Ueda S, Ogata S, Tsuda H, et al. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 2004; 29(1): e1-e8.
37. (Part I). Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis. J Natl Cancer Inst 1998; 90(20): 1529-1536
38. Juuti A, Louhimo J, Nordling S, et al. Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer. J Clin Pathol 2006; 59(4): 382-386
39. Okami J, Yamamoto H, Fujiwara Y, et al. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res 1999; 5(8): 2018-2024
40. Matsubayashi H, Infante JR, Winter J, et al. Tumor COX-2 expression and prognosis of patients with resectable pancreatic cancer. Cancer Biol Ther 2007; 6(10): 1569-1575
41. Hermanova M, Karasek P, Nenutil R, et al. Clinicopathological correlations of cyclooxygenase-2, MDM2, and p53 expressions in surgically resectable pancreatic invasive ductal adenocarcinoma. Pancreas 2009; 38(5): 565-571
42. Kornmann M, Ishiwata T, Itakura J, et al. Increased cyclin D1 in human pancreatic cancer is associated with decreased postoperative survival. Oncology 1998; 55(4): 363-369
43. Lebe B, Sagol O, Ulukus C, et al. The importance of cyclin D1 and Ki67 expression on the biological behavior of pancreatic adenocarcinomas. Pathol Res Pract 2004; 200(5): 389-396
44. Ito Y, Takeda T, Wakasa K, et al. Expression and possible role of cyclin D3 in human pancreatic adenocarcinoma. Anticancer Res 2001; 21(2A): 1043-1048
45. Gong YL, Xu GM, Huang WD, et al. Expression of matrix metalloproteinases and the tissue inhibitors of metalloproteinases and their local invasiveness and metastasis in Chinese human pancreatic cancer. J Surg Oncol 2000; 73(2): 95-99
46. Juuti A, Lundin J, Nordling S, et al. Epithelial MMP-2 expression correlates with worse prognosis in pancreatic cancer. Oncology 2006; 71(1-2): 61-68
47. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297(3): 267-277
48. Mackey JR, Mani RS, Selner M, et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 1998; 58(19): 4349-4357
49. Marechal R, Mackey JR, Lai R, et al. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res 2009; 15(8): 2913-2919
50. Mori R, Ishikawa T, Ichikawa Y, et al. Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells. Oncol Rep 2007; 17(5): 1201-1205
51. Garcia-Manteiga J, Molina-Arcas M, Casado FJ, et al. Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2′,2′-difluorodeoxycytidine- induced cytotoxicity. Clin Cancer Res 2003; 9(13): 5000-5008
52. Spratlin J, Sangha R, Glubrecht D, et al. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res 2004; 10(20): 6956-6961
53. Giovannetti E, Del Tacca M, Mey V, et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 2006; 66(7): 3928-3935
54. Rauchwerger DR, Firby PS, Hedley DW, et al. Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity. Cancer Res 2000; 60(21): 6075-6079
55. Giovannetti E, Mey V, Danesi R, et al. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. Clin Cancer Res 2004; 10(9): 2936-2943
56. Giovannetti E, Mey V, Nannizzi S, et al. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 2005; 68(1): 110-118
57. Ohhashi S, Ohuchida K, Mizumoto K, et al. Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer. Anticancer Res 2008; 28(4B): 2205-2212
58. Kroep JR, Loves WJ, van der Wilt CL, et al. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol Cancer Ther 2002; 1(6): 371-376
59. Abbruzzese JL. New applications of gemcitabine and future directions in the management of pancreatic cancer. Cancer 2002; 95(4 Suppl): 941-945
60. Poplin E, Feng Y, Berlin J, et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009; 27(23): 3778-3785
61. Hinman MN, Lou H. Diverse molecular functions of Hu proteins. Cell Mol Life Sci 2008; 65(20): 3168-3181
62. Costantino CL, Witkiewicz AK, Kuwano Y, et al. The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase. Cancer Res 2009; 69(11): 4567-4572
63. Strimpakos AS, Syrigos KN, Saif MW. Pharmacogenetics in pancreatic cancer. JOP 2009; 10(4): 357-360
64. Ueno H, Kaniwa N, Okusaka T, et al. Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients. Br J Cancer 2009; 100(6): 870-873
65. Mercier C, Raynal C, Dahan L, et al. Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation. Pharmacogenet Genomics 2007; 17(10): 841-844
66. Rosell R, Felip E, Taron M, et al. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin Cancer Res 2004; 10(12 Pt 2): 4215S-9S.
67. Nakahira S, Nakamori S, Tsujie M, et al. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int J Cancer 2007; 120(6): 1355-1363
68. Akita H, Zheng Z, Takeda Y, et al. Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma. Oncogene 2009; 28(32): 2903-2909
69. Rosell R, Cobo M, Isla D, et al. Pharmacogenomics and gemcitabine. Ann Oncol 2006; 17 (Suppl 5): v13-v16.
70. Nakano Y, Tanno S, Koizumi K, et al. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer 2007; 96(3): 457-463
71. Bondar VM, Sweeney-Gotsch B, Andreeff M, et al. Inhibition of the phosphatidylinositol 3′-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther 2002; 1(12): 989-997
72. Lev-Ari S, Vexler A, Starr A, et al. Curcumin augments gemcitabine cytotoxic effect on pancreatic adenocarcinoma cell lines. Cancer Invest 2007; 25(6): 411-418
73. Akada M, Crnogorac-Jurcevic T, Lattimore S, et al. Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer. Clin Cancer Res 2005; 11(8): 3094-3101
74. Erkan M, Kleeff J, Esposito I, et al. Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene 2005; 24(27): 4421-4432
75. Ishida M, Sunamura M, Furukawa T, et al. Elucidation of the relationship of BNIP3 expression to gemcitabine chemosensitivity and prognosis. World J Gastroenterol 2007; 13(34): 4593-4597
76. Diasio RB. Clinical implications of dihydropyrimidine dehydrogenase on 5-FU pharmacology. Oncology (Williston Park) 2001; 15(1 Suppl 2): 21-26
77. Ciaparrone M, Quirino M, Schinzari G, et al. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil. Oncology 2006; 70(5): 366-377
78. Nagakawa T, Kayahara M, Ohta T, et al. Dihydropyrimidine dehydrogenase activity in human pancreatic tumor tissues. Cancer Invest 2000; 18(6): 516-520
79. Nakayama S, Takeda S, Kawase Y, et al. Clinical significance of dihydropyrimidine dehydrogenase in adjuvant 5-fluorouracil liver perfusion chemotherapy for pancreatic cancer. Ann Surg 2004; 240(5): 840-844
80. Moran RG, Spears CP, Heidelberger C. Biochemical determinants of tumor sensitivity to 5-fluorouracil: ultrasensitive methods for the determination of 5-fluoro-2′-deoxyuridylate, 2′-deoxyuridylate, and thymidylate synthetase. Proc Natl Acad Sci USA 1979; 76(3): 1456-1460
81. Kang SP, Saif MW. Pharmacogenomics and pancreatic cancer treatment. Optimizing current therapy and individualizing future therapy. JOP 2008; 9(3): 251-266
82. Yin MB, Zakrzewski SF, Hakala MT. Relationship of cellular folate cofactor pools to the activity of 5-fluorouracil. Mol Pharmacol 1983; 23(1): 190-197
83. Shimoda M, Sawada T, Kubota K. Thymidylate synthase and dihydropyrimidine dehydrogenase are upregulated in pancreatic and biliary tract cancers. Pathobiology 2009; 76(4): 193-198
84. Uchida K, Danenberg PV, Danenberg KD, et al. Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine. BMC Cancer 2008; 8: 386.
85. Beck A, Etienne MC, Cheradame S, et al. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer 1994; 30A(10): 1517-1522
86. Mori K, Hasegawa M, Nishida M, et al. Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues. Int J Oncol 2000; 17(1): 33-38
87. Soong R, Shah N, Salto-Tellez M, et al. Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. Ann Oncol 2008; 19(5): 915-919
88. Hong SP, Shin SK, Bang S, et al. Prognostic value of thymidine phosphorylase expression for pancreatic cancer. Hepatogastroenterology 2009; 56(93): 1178-1182
89. Tsukamoto Y, Kato Y, Ura M, et al. A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU. Pharm Res 2001; 18(8): 1190-1202
90. Zhang X, Diasio RB. Regulation of human dihydropyrimidine dehydrogenase: implications in the pharmacogenetics of 5-FU-based chemotherapy. Pharmacogenomics 2007; 8(3): 257-265
91. Amstutz U, Farese S, Aebi S, et al. Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy. J Exp Clin Cancer Res 2008; 27: 54.
92. Ishikawa T, Sekiguchi F, Fukase Y, et al. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 1998; 58(4): 685-690
93. Nishimura G, Terada I, Kobayashi T, et al. Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5′-deoxy-5-fluorouridine as adjuvant chemotherapy. Oncol Rep 2002; 9(3): 479-482
94. Miyake K, Imura S, Yoshizumi T, et al. Role of thymidine phosphorylase and orotate phosphoribosyltransferase mRNA expression and its ratio to dihydropyrimidine dehydrogenase in the prognosis and clinicopathological features of patients with pancreatic cancer. Int J Clin Oncol 2007; 12(2): 111-119
95. Saif MW, Hashmi S, Bell D, et al. Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase/ dihydropyrimidine dehydrogenase ratio and its correlation with survival. Expert Opin Drug Saf 2009; 8(5): 507-514
96. Lecomte T, Ferraz JM, Zinzindohoue F, et al. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res 2004; 10(17): 5880-5888
97. Schwab M, Zanger UM, Marx C, et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 2008; 26(13): 2131-2138
98. Sharma R, Hoskins JM, Rivory LP, et al. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients. Clin Cancer Res 2008; 14(3): 817-825
99. Wang L, Miao X, Tan W, et al. Genetic polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase and risk of pancreatic cancer. Clin Gastroenterol Hepatol 2005; 3(8): 743-751
100. Marcuello E, Altes A, Menoyo A, et al. Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy? Cancer Chemother Pharmacol 2006; 57(6): 835-840
101. Clarke DJ, Moghrabi N, Monaghan G, et al. Genetic defects of the UDP-glucuronosyltransferase-1 (UGT1) gene that cause familial non-haemolytic unconjugated hyperbilirubinaemias. Clin Chim Acta 1997; 266(1): 63-74.
102. Cote JF, Kirzin S, Kramar A, et al. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res 2007; 13(11): 3269-3275
103. Iyer L, Das S, Janisch L, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002; 2(1): 43-47
104. Kweekel DM, Gelderblom H, Van der ST, et al. UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study. Br J Cancer 2008; 99(2): 275-282
105. Kim TW, Innocenti F. Insights, challenges, and future directions in irinogenetics. Ther Drug Monit 2007; 29(3): 265-270
106. Bellott R, Le MV, Charasson V, et al. Functional study of the 830C>G polymorphism of the human carboxylesterase 2 gene. Cancer Chemother Pharmacol 2008; 61(3): 481-488
107. Charasson V, Bellott R, Meynard D, et al. Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38. Clin Pharmacol Ther 2004; 76(6): 528-535
108. Matzow T, Cowen RL, Williams KJ, et al. Hypoxia-targeted overexpression of carboxylesterase as a means of increasing tumour sensitivity to irinotecan (CPT-11). J Gene Med 2007; 9(4): 244-252
109. Mathijssen RH, Marsh S, Karlsson MO, et al. Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res 2003; 9(9): 3246-3253
110. Sai K, Kaniwa N, Itoda M, et al. Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics 2003; 13(12): 741-757
111. de Jong FA, Scott-Horton TJ, Kroetz DL, et al. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin Pharmacol Ther 2007; 81(1): 42-49
112. Felip E, Rosell R. Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response. Expert Rev Mol Diagn 2007; 7(3): 261-268
113. Dabholkar M, Bostick-Bruton F, Weber C, et al. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 1992; 84(19): 1512-1517
114. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002; 8(7): 2286-2291
115. Booton R, Ward T, Ashcroft L, et al. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. J Thorac Oncol 2007; 2(10): 902-906
116. Azzoli CG, Baker S., Jr, Temin S, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009; 27(36): 6251-6266
117. Zhou W, Gurubhagavatula S, Liu G, et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 2004; 10(15): 4939-4943
118. Kalikaki A, Kanaki M, Vassalou H, et al. DNA repair gene polymorphisms predict favorable clinical outcome in advanced nonsmall-cell lung cancer. Clin Lung Cancer 2009; 10(2): 118-123
119. Kamikozuru H, Kuramochi H, Hayashi K, et al. ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy. Int J Oncol 2008; 32(5): 1091-1096
120. Quinn JE, Kennedy RD, Mullan PB, et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003; 63(19): 6221-6228
121. Chaudhry P, Srinivasan R, Patel FD. Utility of gene promoter methylation in prediction of response to platinum-based chemotherapy in epithelial ovarian cancer (EOC). Cancer Invest 2009; 27(8): 877-884
122. Moufarij MA, Phillips DR, Cullinane C. Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines. Mol Pharmacol 2003; 63(4): 862-869
123. Pare L, Marcuello E, Altes A, et al. Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. Br J Cancer 2008; 99(7): 1050-1055
124. Shirota Y, Stoehlmacher J, Brabender J, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001; 19(23): 4298-4304
125. Longley DB, McDermott U, Johnston PG. Clinical significance of prognostic and predictive markers in colorectal cancer. Pharmacogenomics J 2002; 2(4): 209-216
126. Stoehlmacher J, Ghaderi V, Iobal S, et al. A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res 2001; 21(4B): 3075-3079
127. Stoehlmacher J, Park DJ, Zhang W, et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 2004; 91(2): 344-354
128. Glasgow SC, Yu J, Carvalho LP, et al. Unfavourable expression of pharmacologic markers in mucinous colorectal cancer. Br J Cancer 2005; 92(2): 259-264
129. Trachte AL, Suthers SE, Lerner MR, et al. Increased expression of alpha-1-antitrypsin, glutathione S-transferase pi and vascular endothelial growth factor in human pancreatic adenocarcinoma. Am J Surg 2002; 184(6): 642-647
130. Lecomte T, Landi B, Beaune P, et al. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 2006; 12(10): 3050-3056
131. Gamelin L, Capitain O, Morel A, et al. Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway. Clin Cancer Res 2007; 13(21): 6359-6368
132. Mahtani RL, Macdonald JS. Synergy between cetuximab and chemotherapy in tumors of the gastrointestinal tract. Oncologist 2008; 13(1): 39-50.
133. Balin-Gauthier D, Delord JP, Pillaire MJ, et al. Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation. Br J Cancer 2008; 98(1): 120-128
134. Lee J, Jang KT, Ki CS, et al. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer 2007; 109(8): 1561-1569
135. Buck E, Eyzaguirre A, Haley JD, et al. Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity. Mol Cancer Ther 2006; 5(8): 2051-2059
136. Zalatnai A, Molnar J. Molecular background of chemoresistance in pancreatic cancer. In Vivo 2007; 21(2): 339-347
137. Siu LL, Awada A, Takimoto CH, et al. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res 2006; 12(1): 144-151
138. Andrianifahanana M, Moniaux N, Schmied BM, et al. Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance. Clin Cancer Res 2001; 7(12): 4033-4040
139. Chaturvedi P, Singh AP, Moniaux N, et al. MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins. Mol Cancer Res 2007; 5(4): 309-320
140. Singh AP, Moniaux N, Chauhan SC, et al. Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis. Cancer Res 2004; 64(2): 622-630
141. Zhang Y, Dang C, Ma Q, et al. Expression of nerve growth factor receptors and their prognostic value in human pancreatic cancer. Oncol Rep 2005; 14(1): 161-171
142. Schneider MB, Standop J, Ulrich A, et al. Expression of nerve growth factors in pancreatic neural tissue and pancreatic cancer. J Histochem Cytochem 2001; 49(10): 1205-1210
143. Ma J, Jiang Y, Jiang Y, et al. Expression of nerve growth factor and tyrosine kinase receptor A and correlation with perineural invasion in pancreatic cancer. J Gastroenterol Hepatol 2008; 23(12): 1852-1859
144. Zhu Z, Friess H, diMola FF, et al. Nerve growth factor expression correlates with perineural invasion and pain in human pancreatic cancer. J Clin Oncol 1999; 17(8): 2419-2428
145. Garcia-Bailo B, Toguri C, Eny KM, et al. Genetic variation in taste and its influence on food selection. OMICS 2009; 13(1): 69-80.
146. Wilke RA, Mareedu RK, Moore JH. The pathway less traveled: moving from candidate genes to candidate pathways in the analysis of genome-wide data from large scale pharmacogenetic association studies. Curr Pharmacogenomics Person Med 2008; 6(3): 150-159
147. Fackler JL, McGuire AL. Paving the way to personalized genomic medicine: Steps to successful implementation. Curr Pharmacogenomics Person Med 2009; 7(2): 125-132
148. Deshmukh VG, Hoffman MA, Arnoldi C, et al. Efficiency of CYP2C9 genetic test representation for automated pharmacogenetic decision support. Methods Inf Med 2009; 48: 282-290